Patent details

EP2906251 Title: PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
EP2906251
WO Application Number:
EP2013071352
Type:
European Patent Granted for NL
Status:
Patent in Force
Publication Title:
Title When Made Available For Viewing:
Reason Lapsed:
Application number:
EP13786186.0
WO Publication Number:
WO2014057122
EPO Publication Language:
English
SPC Number:
First Applicant Residence Country:
Switzerland (CH)
Publications:

Dates

Filing date:
11/10/2013
Grant date:
27/09/2017
EP Publication Date:
19/08/2015
WO Publication Date:
17/04/2014
Claims Translations Received Date:
Claims Translation B1 Received Date:
21/12/2017
Claims Translation B2 Received Date:
Claims Translation B3 Received Date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Published:
Due To Cession Date:
Registration date:
27/09/2017
EP B1 Publication Date:
27/09/2017
EP B2 Publication Date:
EP B3 Publication Date:
Description Translation B1 Received Date:
Description Translation B2 Received Date:
Description Translation B3 Received Date:
Expiration date:
10/10/2033
Lapsed By Expiration Date:
Patent Validated Date:
11/01/2018
Revocation Date:
Invalidity Date:
Response To Novelty Search Report Received:
Patent Granting Request:
Lapsed date:

Applicant/holder

From:
27/09/2022
 
 

 

Name:
ADC Therapeutics SA
Address:
Biopôle Route de la Corniche 3B, 1066, Epalinges, Switzerland (CH)

From:
27/09/2017
 
 

 

Name:
Medimmune Limited
Address:
Milstein Building Granta Park, CAMBRIDGE, CAMBRIDGESHIRE CB21 6GH, United Kingdom (GB)

Historical Applicant/holder

From:
27/09/2017
To:
27/09/2022

 

Name:
ADC Therapeutics SA
Address:
Route de la Corniche 3B, 1066 Epalinges, Switzerland (CH)

Agent

Name:
ir. M.F.J.M. Ketelaars c.s.
From:
10/01/2018
Address:
NLO Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:

Inventor

1

Name:
VAN BERKEL, Patricius Hendrikus Cornelis
Address:
1003 Lausanne, Switzerland (CH)

2

Name:
HOWARD, Philip Wilson
Address:
London Greater London E1 2AX, United Kingdom (GB)

Pledgee

Name:
Owl Rock Opportunistic Master Fund I, L.P.
Address:
399 Park Avenue, 38th FL, 10022, New York, NY, United States of America (US)

Priority

1

Priority Patent Number:
201361794954 P
Priority Date:
15/03/2013
Priority Country:
United States of America (US)

2

Priority Patent Number:
201361794922 P
Priority Date:
15/03/2013
Priority Country:
United States of America (US)

3

Priority Patent Number:
201361794997 P
Priority Date:
15/03/2013
Priority Country:
United States of America (US)

4

Priority Patent Number:
201261712928 P
Priority Date:
12/10/2012
Priority Country:
United States of America (US)

5

Priority Patent Number:
201261712924 P
Priority Date:
12/10/2012
Priority Country:
United States of America (US)

Classification

IPC or IDT classification:
A61K 31/551; A61K 39/395; A61P 35/02; C07K 16/28; C07K 16/30; A61K 47/68;

Publication

Bulletin

1

Bulletin Heading:
MED
Journal edition number:
47/23
Publication date:
22/11/2023
Description:
Other communications

2

Bulletin Heading:
MED
Journal edition number:
40/22
Publication date:
05/10/2022
Description:
Other communications

3

Bulletin Heading:
MED
Journal edition number:
29/20
Publication date:
14/08/2020
Description:
Other communications

4

Bulletin Heading:
EP3
Journal edition number:
04/18
Publication date:
17/01/2018
Description:
European patents granted for the Netherlands in which a translation was filed ex Article 52 par. 1 of the NL Patent Law 1995

5

Bulletin Heading:
EP2
Journal edition number:
39/17
Publication date:
27/09/2017
Description:
European patents granted for the Netherlands

European Patent Bulletin

Issue number:
201739
Publication date:
27/09/2017
Description:
Grant (B1)

Deed

Right of Pledge

Change Kind/ Decision Type:
Removed
Deed Number:
RC202302251A
Date Registered:
08/11/2023
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
dr. R.C. van Duijvenbode c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Removed Pledgee(s)

Name:
Deerfield Partners, L.P.
Address:
780 Third Avenue, 37th Floor, 10017, New York, NY, United States of America (US)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Change of Address

Change Kind/ Decision Type:
Owner
Deed Number:
RC202202466A
Date Registered:
27/09/2022
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
dr. R.C. van Duijvenbode c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Right of Pledge

Change Kind/ Decision Type:
Established
Deed Number:
RC202202466B
Date Registered:
27/09/2022
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
dr. R.C. van Duijvenbode c.s.
Journal Edition Number:
Text:
Aandeel van ADC Therapeutics SA is verpand aan Owl Rock Opportunistic Master Fund I, L.P.
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Added Pledgee(s)

Name:
Owl Rock Opportunistic Master Fund I, L.P.
Address:
399 Park Avenue, 38th FL, 10022, New York, NY, United States of America (US)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Right of Pledge

Change Kind/ Decision Type:
Established
Deed Number:
RC202001210A
Date Registered:
25/06/2020
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. M.F.J.M. Ketelaars c.s.
Journal Edition Number:
Text:
Het aandeel van ADC Therapeutics SA is verpand.
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Added Pledgee(s)

Name:
Deerfield Partners, L.P.
Address:
780 Third Avenue, 37th Floor, 10017, New York, NY, United States of America (US)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Annual Fee

Annual Fee(s) Due Date:
31/10/2025
Annual Fee Number:
13
Annual Fee Amount:
700 Euro
Last Annual Payment Date:
23/09/2024
Last Annual Fee Paid Number:
12
Last Annual Fee Paid Amount:
600 Euro
Payer:
Mewburn Ellis LLP
Filing date Document type Document Description Number of pages File Type
10/01/2018 Outgoing Correspondence Letter no formal defects 1 PDF /1/5/1/9/9/0800199151/docs/ep13786186.0_2_186133l271.pdf
21/12/2017 Claims First filed claims 3 PDF /1/5/1/9/9/0800199151/docs/ep13786186.0_0_claims20171221124037271.pdf
21/12/2017 Incoming Correspondence Electronic Accompanying letter incoming document 2 PDF /1/5/1/9/9/0800199151/docs/ep13786186.0_1_incomingcorrespondenceelectronic20171221124037945.pdf